KLK3 and prostate carcinoma: There is growing evidence demonstrating the clinical impact CP4 has in relation to worse clinical outcomes, including prostate-specific antigen (PSA) failure, recurrence-free survival, distant metastases, and prostate cancer-related mortality.6